>Cirugía y Cirujanos
>Year 2011, Issue 5
López-Alarcón M, Chávez-Negrete A, Montalvo-Velarde I, Maldonado-Hernández J, Vital-Reyes VS
Homocysteine after a methionine load in healthy subjects with adequate B-vitamin status
Cir Cir 2011; 79 (5)
PDF: 475.61 Kb.
[Full text - PDF]
Background: Plasma homocysteine (Hcy) determination at 6-8 h after an oral methionine load (OML) allows for identification of some, but not all, individuals at risk to develop cardiovascular disease. It is probable that in some cases the Hcy increases occur later, or it elevates between normal ranges but in a sustained manner. However, the entire Hcy response curve has not been described. We undertook this study to determine Hcy concentrations from baseline to 24- and 48-h after an OML in non-B-vitamin deficient adult subjects with other risk factors for high levels of Hcy such as smoking and overweight.
Methods: In a cross-over, clinical design, Hcy concentrations were determined at 2-h intervals throughout 12 h and at 24 h and 48 h after an OML (0.1 g/kg). Hcy and vitamin B6 (VB6) concentrations were measured by high-performance liquid chromatography (HPLC). Folic acid (FA) and vitamin B12 (VB12) were measured by radioimmunoassay (RIA). Statistical analysis included delta values and areas under the curve. Student t-test and repeated measurement analyses were conducted to control for confounders.
Results: Twenty nine subjects with adequate Hcy, FA, VB6 and VB12 status were included. The maximum Hcy concentration occurred 8 h after the load and returned to baseline concentrations after 24 h. All subjects presented Hcy after the load within normal ranges, but smoking and overweight synergistically influenced the response to the challenge, producing a sustained elevation after the dose.
Conclusions: Hcy concentrations after an OML remained above baseline for at least 24 h. Smoking and overweight affected the response to the methionine challenge.
||Homocysteine response, oral methionine test, folic acid, vitamin B6, vitamin B12.
Warren CJ. Emergent cardiovascular risk factor: homocysteine. Prog Cardiovasc Nurs 2002;17:35-41.
Wald DS, Law M, Morris JK. Homocysteine and cardiovascular disease: evidence on causality from a meta-analysis. BMJ 2002;325:1202-1206.
Bostom AG, Jacques PF, Nadeau MR, Williams RR, Ellison RC, Selhub J. Post-methionine load hyperhomocysteinemia in persons with normal fasting total homocysteine: initial results from the NHLBI Family Heart Study. Atherosclerosis 1995;116:147-151.
van der Griend R, Haas FJ, Duran M, Biesma DH, Meuwissen OJ, Banga JD. Methionine loading test is necessary for detection of hyperhomocysteinemia. J Lab Clin Med 1998;132:67-72.
van der Griend R, Biesma DH, Banga JD. Postmethionine-load homocysteine determination for the diagnosis of hyperhomocysteinemia and efficacy of homocysteine lowering treatment regimens. Vasc Med 2002;7:29-33.
den Heijer M, Graafsma S, Lee SY, van Landerghem B, Kluijtmans L, Verhoef P, et al. Homocysteine levelsbefore and after methionine loadingin 51 Dutch families. Eur J Hum Genet 2005;13:753-762.
Hanratty CG, McGrath LT, McAuley DF, Young IS, Johnston GD. The effects of oral methionine and homocysteine on endothelial function. Heart 2001;85:326-330.
Selhub J. The many facets of hyperhomocysteinemia: studies from the Framingham cohorts. J Nutr 2006;136:1726S-1730S.
Haulrik N, Toulbro S, Dyerberg J, Stender S, Skov AR, Astrup A. Effect of protein and methionine intakes on plasma homocysteine concentrations: a six-mo randomized controlled trial on overweight subjects. Am J Clin Nutr 2002;76:1202-1206.
Verhoef P, van Vliet T, Olthof MR, Katan MB. High-protein diet increases postprandial but not fasting plasma homocysteine concentrations: a dietary controlled, crossover trial in healthy volunteers. Am J Clin Nutr 2005;82:553-558.
Ward M, McNulty H, McPartlin J, Strain JJ, Weir DG, Scott JM. Effect of supplemental methionine on plasma homocysteine concentration in healthy men: a preliminary study. Int J Vitam Nutr Res 2001;71:82-86.
Sassi S, Cosmi B, Palareti G, Legnani C, Grossi G, Musolesi S, et al. Influence of age, sex and vitamin status on fasting and post-methionine load plasma homocysteine levels. Haematologica 2002;87:957-964.
Ganji V, Kafai MR. Demographic, lifestyle, and health characteristics and serum B vitamin status are determinants of plasma total homocysteine concentration in the post-folic acid fortification period, 1999-2004. J Nutr 2009;139:345-352.
O’Callaghan P, Meleady R, Fitzgerald T, Graham I, and the European COMAC Group. Smoking and plasma homocysteine. Eur Heart J 2002;23:1580-1586.
Tungtrongchitr R, Pongpaew P, Tongboonchoo C, Vudhivai N, Changbumrung S, Tungtrongchitr A, et al. Serum homocysteine, B12 and folic acid concentration in Thai overweight and obese subjects. Int J Vitam Nutr Res 2003;73:8-14.
Refsum H, Nurk E, Smith AD, Ueland PM, Gjesdal CG, Bjelland I, et al. The Hordaland Homocysteine Study: a community-based study of homocysteine, its determinants, and associations with diseases. J Nutr 2006;136:1731S-1740S.
IOM (Institute of Medicine). Dietary Reference Intakes for Thiamin, Riboflavin, Niacin, Vitamin B6, Folate, Vitamin B12, Pantothenic Acid, Biotin, and Choline. Washington, DC: National Academy Press; 2000. pp. 150-348.
Klee GG. Cobalamin and folate evaluation: measurement of methylmalonic acid and homocysteine vs vitamin B12 and folate. Clin Chem 2000;46:1277-1283.
Senti FR, Pilch SM. Analysis of folate data from the second National Health and Nutrition Examination Survey (NHANES II). J Nutr 1985;115:1398-1402.
Reis RP, Azinheira J, Reis HP, Pina JE, Correia JM, Luís AS. Influence of smoking on homocysteinemia at baseline and after methionine load. Rev Port Cardiol 2000;19:471-474.
Vermaak WJ, Ubbink JB, Barnard HC, Potgieter GM, van Jaarsveld H, Groenewald AJ. Vitamin B6 nutritional status and cigarette smoking. Am J Clin Nutr 1990;51:1058-1061.
Vassalle C, Maffei S, Ndreu R, Mercuri A. Age-related oxidative stress modulation by smoking habit and obesity. Clin Biochem 2009;42:739-741.
Wald DS, Morris JK, Law M, Wald NJ. Folic acid, homocysteine and cardiovascular disease: judging causality in the face of inconclusive trial evidence. BMJ 2006;333:1113-1117.
Ueland PM, Hustad S, Schneede J, Refsum H, Vollset SE. Biological and clinical implications of the MTHFR C677T polymorphism. Trends Pharmacol Sci 2001;22:195-201.
Guéant-Rodríguez RM, Guéant JL, Debard R, Thirion S, Hong LX, Bronowicki JP, et al. Prevalence of methylenetetrahydrofolate reductase 677T and 1298C alleles and folate status: a comparative study in Mexican, West African, and European populations. Am J Clin Nutr 2006;83:701-707.
>Cirugía y Cirujanos
>Year 2011, Issue 5